MDACC Study No:2011-0513 ( NCT No: NCT01351935)
Title:Phase 1b, Escalating Dose Study of AVL-292, a Bruton’s Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma,
Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia
Principal Investigator:Jan A. Burger
Treatment Agent:AVL-292
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the recommended dose of
AVL-292 that researchers think may work best in the treatment of patients with
relapsed or refractory B-NHL, CLL, or WM. The safety of this drug will also be

AVL-292 is designed to block the function of an enzyme that helps B cells
work. B cells are white blood cells that are the targets of B-NHL, CLL, and
WM. By blocking the function of this enzyme, AVL-292 may or may not cause the
tumor to shrink.

This is an early study using AVL-292 in humans.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:AVL-292
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Avila Therapeutics
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jan A. Burger
For Clinical Trial Enrollment:713-792-1865
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults